Technical Analysis for GILD - Gilead Sciences, Inc.

Grade Last Price % Change Price Change
grade C 65.07 1.97% 1.26
GILD closed up 1.97 percent on Friday, November 15, 2019, on 1.2 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Flat Up Up
See historical GILD trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Centerline Cross Bullish 0.00%
Lower Bollinger Band Touch Weakness 1.97%
MACD Bearish Centerline Cross Bearish 2.75%
Down 3 Days in a Row Weakness 2.75%
20 DMA Resistance Bearish 1.17%
Fell Below 50 DMA Bearish 1.17%
MACD Bearish Signal Line Cross Bearish 1.17%
NR7 Range Contraction 1.17%

Older signals for GILD ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Its products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; and Viread and Hepsera products for the treatment of liver disease. The company also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, it provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular macular degeneration. Further, it has product candidates in various stages for the treatment of cardiovascular diseases, respiratory diseases, and oncology diseases/inflammation. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, GSK, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Medicine Chemistry Biopharmaceutical Diseases Infection Organic Chemistry Cystic Fibrosis HIV Cardiovascular Diseases Pulmonary Arterial Hypertension Hepatotoxins Respiratory Diseases Gilead Sciences Prodrugs AIDS Cytomegalovirus Retinitis Fungal Infections Liver Disease Tenofovir Disoproxil
Is GILD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 72.9
52 Week Low 60.32
Average Volume 5,771,460
200-Day Moving Average 65.3106
50-Day Moving Average 64.5936
20-Day Moving Average 64.6065
10-Day Moving Average 64.646
Average True Range 1.3022
ADX 13.72
+DI 22.8318
-DI 27.3903
Chandelier Exit (Long, 3 ATRs ) 62.8434
Chandelier Exit (Short, 3 ATRs ) 66.2866
Upper Bollinger Band 66.5872
Lower Bollinger Band 62.6258
Percent B (%b) 0.62
BandWidth 6.131581
MACD Line 0.0055
MACD Signal Line 0.0445
MACD Histogram -0.039
Fundamentals Value
Market Cap 84.98 Billion
Num Shares 1.31 Billion
EPS 9.21
Price-to-Earnings (P/E) Ratio 7.07
Price-to-Sales 3.57
Price-to-Book 4.49
PEG Ratio -1.08
Dividend 2.08
Dividend Yield 3.20%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 66.90
Resistance 3 (R3) 66.75 65.98 66.60
Resistance 2 (R2) 65.98 65.52 66.06 66.49
Resistance 1 (R1) 65.53 65.23 65.76 65.68 66.39
Pivot Point 64.76 64.76 64.88 64.84 64.76
Support 1 (S1) 64.31 64.30 64.54 64.46 63.75
Support 2 (S2) 63.54 64.01 63.62 63.65
Support 3 (S3) 63.09 63.54 63.55
Support 4 (S4) 63.24